Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis

Author(s): Jorg H.W. Distler, Oliver Distler

Journal Name: Current Rheumatology Reviews

Volume 6 , Issue 4 , 2010

Become EABM
Become Reviewer


In the last years, several key-pathways for the aberrant activation of fibroblasts in SSc have been identified in pre-clinical studies. This review summarizes recently identified molecular targets for novel anti-fibrotic approaches in systemic sclerosis (SSc) and other fibrotic disorders. We will focus on pathways that can be targeted by drugs that are either already approved for other indications or that are currently evaluated in clinical trials.

Keywords: Fibrosis, scleroderma, molecular-targeted therapies, Anti-Fibrotic Approaches, Systemic Sclerosis, 5-hydroxy-trypthamine, pro-fibrotic effects, tight-skin 1 (tsk-1), HISTONE DEACETYLASE INHIBITORS, Hyperacetylation, HDACs, anti-fibrotic effects, transcriptional coactivators, multiple malignancies, neoplastic diseases, leukaemia, procainamide, hydralazine, cardiac arrhythmias, RE-CEPTOR γ AGONISTS, PPARγ agonists, Sonic Hedgehog (Shh)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [305 - 308]
Pages: 4
DOI: 10.2174/157339710793205666
Price: $65

Article Metrics

PDF: 3